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Purpose: To evaluate the evolution of morphologic features of auto-
immune pancreatitis (AIP) at computed tomography (CT)
and to identify imaging features that can predict AIP re-
sponse to corticosteroid therapy (CST).
Materials and
Methods:
This HIPAA-compliant retrospective study had institu-
tional review board approval. From among a cohort of 63
patients with AIP, 15 patients (12 men, three women;
mean age, 64.7 years; age range, 30–84 years) who un-
derwent sequential CT examinations before treatment
were included to assess the evolution of disease by review-
ing pancreatic, peripancreatic, and ductal changes. Of
these patients, 13 received CST and underwent posttreat-
ment CT; these CT studies were evaluated to determine if
there were imaging features that could predict response to
CST.
Results: The disease evolved from changes of diffuse (14 of 15
patients) or focal (one of 15 patients) parenchymal swell-
ing, peripancreatic stranding (10 of 15 patients), “halo”
(nine of 15 patients), pancreatic duct changes (15 of 15
patients), and distal common bile duct narrowing (12 of 15
patients) to either resolution or development of ductal
strictures and/or focal masslike swelling. In 13 patients
treated with CST, favorable response to treatment was
seen in those with diffuse pancreatic and peripancreatic
changes. Suboptimal response was seen in patients with
ductal stricture formation (two of 13 patients) and in those
in whom focal masslike swellings persisted after resolution
of diffuse changes (seven of 13 patients).
Conclusion: CT features like diffuse swelling and halo respond favor-
ably to CST and likely reflect an early inflammatory phase,
whereas features like ductal strictures and focal masslike
swelling are predictive of a suboptimal response and sym-
bolize a late stage with predominance of fibrosis.
 RSNA, 2008
Supplemental material: http://radiology.rsnajnls.org/cgi
/content/full/2493080279/DC1
1 From the Departments of Radiology (D.V.S., N.I.S.), Pa-
thology (V.D.), Gastroenterology (D.L.F.), and Surgery
(C.F.), Massachusetts General Hospital–Harvard Medical
School, 55 Fruit St, White 270, Boston, MA 02114; and
Aga Khan University, Karachi, Pakistan (M.S.S.). Received
February 11, 2008; revision requested April 22; revision
received June 10; accepted June 17; final version ac-
cepted July 11. Address correspondence to D.V.S.
(e-mail: dsahani@partners.org ).
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Autoimmune pancreatitis (AIP) isbeing increasingly recognized be-cause of growing awareness of
the disease and improved understand-
ing of its imaging features. Surgical re-
section, which was once frequently per-
formed for management of AIP, has
provided an opportunity to study the
histopathologic features of a number of
specimens (1–4). This, in turn, has led
to an improved understanding of the
disease’s biology and to increased use of
corticosteroid therapy (CST) (5). The
varied clinical manifestations of AIP
range from mild, nonspecific complaints
to the more ominous symptom of ob-
structive jaundice mimicking pancreatic
malignancy (6). Although clinically the
disease might resemble malignancy of
the pancreas or, occasionally, other
forms of pancreatitis, the characteristic
imaging, clinical, and laboratory fea-
tures that have been described, as well
as its response to CST, have allowed
classification of this pathologic process
as a separate disease entity (6). A re-
cent study (7) investigated the benefits
of CST over mere observation in terms
of complete remission rate, recurrence
rate, and period of time needed to
achieve complete remission, and clear
advantages with the use of CST were
found; CST has therefore been recom-
mended as a standard initial therapy for
AIP.
The features of AIP at computed to-
mography (CT) have also been reported
to be quite varied. The presence of dif-
fuse or focal enlargement of the pan-
creas, with or without “halo,” and the
presence of featureless homogeneous
morphology are considered characteris-
tic of AIP (8–11). In few cases, a focal
masslike swelling, often in the pancre-
atic head, can be present (8–12). Other
features, such as retraction of the pan-
creatic tail, segmental or diffuse nar-
rowing of the pancreatic duct (PD), in-
volvement of the distal common bile
duct (CBD), and multiple cholangitis-
like bile duct strictures, have been de-
scribed (8,9,11,13). This spectrum of
imaging findings raises the question of a
sequential progression of the disease
over time. Moreover, the response of
AIP to CST has also been variable, from
complete resolution of symptoms and
imaging findings to variable degrees of
partial response and recurrent disease
(14–19).We hypothesize that these differ-
ences in imaging features and responses
to CST may be related to different
phases of AIP. Understanding the se-
quence of events associated with AIP
can enable early diagnosis of the disease
and identify morphologic features that
can predict response to medical treat-
ment.
We undertook this retrospective
analysis to evaluate the evolution of
morphologic features of AIP at CT and
to identify imaging features that can
predict AIP response to CST.
Materials and Methods
Patient Selection
The institutional review board of our
hospital approved this Health Insurance
Portability and Accountability Act–
compliant retrospective study and
waived the need for informed consent.
An electronic database of 63 patients
with a diagnosis of AIP on the basis of
the combination of clinical findings and
imaging features (CT or magnetic reso-
nance imaging) that was supported by
laboratory parameters, results of endo-
scopic retrograde cholangiopancreatogra-
phy (ERCP), and/or results of endo-
scopic ultrasonography (US) with fine-
needle aspiration cytology (14) in our
hospital from July 1995 to July 2007 was
retrospectively reviewed (N.I.S., with 6
years of experience). The diagnosis in
these patients was confirmed with per-
cutaneous biopsy (n  18), analysis of
surgical specimens (n  25), or re-
Published online before print
10.1148/radiol.2493080279
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Abbreviations:
AIP  autoimmune pancreatitis
CBD  common bile duct
CST  corticosteroid therapy
ERCP  endoscopic retrograde cholangiopancreatography
IgG  immunoglobulin G
IgG4  immunoglobulin G4
PD  pancreatic duct
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Advances in Knowledge
 Features of autoimmune pancre-
atitis (AIP) at CT reflect various
phases of disease evolution; the
features associated with inflam-
matory changes of the disease can
resolve completely with timely
institution of corticosteroid ther-
apy (CST).
 Response to CST can be moni-
tored with CT and improvement
in disease status can be measured
within a few weeks of the institu-
tion of CST.
 Improvements in imaging features
at CT are also supported by the
resolution of clinical symptoms
and laboratory findings.
Implications for Patient Care
 Recognition of certain imaging
features such as diffuse pancreatic
swelling and peripancreatic halo
and/or stranding at CT can pre-
dict a favorable outcome after
CST and therefore can be crucial
in deciding appropriate care and
avoiding surgery for these pa-
tients.
 AIP is prone to chronicity and re-
currence, which can be suggested
by imaging features such as either
partial resolution of swelling, loss
of lobularity, or halo or reappear-
ance of these findings after an ini-
tial response; this appearance of
chronicity or recurrence can de-
termine the need for a longer or
repeat dosage of corticosteroids
at appropriate times to achieve
complete resolution.
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sponse to CST at follow-up (n  20).
Patients either were medically treated
with CST (n  25), underwent surgery
(n  25), or did not receive any treat-
ment (n  13). The radiology depart-
ment, in collaboration with the surgical,
endoscopy, and pathology departments,
had been maintaining a database since
2000, and cases had been added to the
database as and when a diagnosis was
made. Fifteen patients who underwent
pretreatment serial contrast material–
enhanced CT examinations were identi-
fied and were included in this study for
evaluating the evolution of CT features
before CST. Of these patients, 13 were
treated with CST; data in these patients
were used to assess response to CST.
Patients and Treatment Strategies
The 15 patients with serial CT studies
included in this investigation ranged in
age from 30 to 84 years (mean age, 64.7
years). Twelve patients were men
(mean age, 63.8 years; age range,
30–83 years), and three were women
(mean age, 68.3 years; age range,
57–84 years). Thirteen of these pa-
tients were treated with CST, and two
underwent surgery. The protocol for
CST therapy included 40 mg of pred-
nisone per day for 4 weeks, followed by
gradual tapering by 5 mg every 2 weeks
until the dose reached 15 mg per day
and then gradual tapering again by 2.5
mg every 4–8 weeks. Three of the 13
patients who received CST later under-
went surgery because of persisting clin-
ical symptoms. Two patients were
treated solely with surgery after fol-
low-up examinations because of a clini-
cal suspicion of a mass in the pancreatic
head (choledochojejunostomy with bi-
opsy of head lesion) or tail (distal pan-
createctomy).
Clinical Features and Laboratory Data
Clinical symptoms at presentation such as
abdominal pain, jaundice, weight loss,
and their improvement or exacerbation
after CST were recorded in a standard-
ized database (N.I.S.). Any history of pre-
vious pancreatitis, alcohol abuse, and au-
toimmune disease was also recorded.
Serum immunoglobulin G (IgG) and im-
munoglobulin G4 (IgG4) levels were
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noted before and after treatment.
Changes in the values at follow-up were
assessed and correlated with imaging fea-
tures (N.I.S.).
Multidetector CT and Image Analysis
All examinations were performed with a
multidetector CT scanner with 4–16 de-
tectors (LightSpeed; GE Medical Sys-
tems, Milwaukee, Wis) before and after
intravenous administration of nonionic
iodinated contrast material (iopamidol,
Isovue 300; Bracco Diagnostics, Prince-
ton, NJ). The scanning was performed
with a maximum section thickness of 5
mm and a minimum section thickness of
1.25 mm. Postprocessed reconstructed
images of the pancreas in coronal and
oblique planes were available for 10 of
15 patients.
A single reader (D.V.S., with 13
years of radiology experience with spe-
cial expertise in pancreatic imaging)
who was aware of the purpose of this
study performed the image analysis.
The CT studies of each patient were
interpreted sequentially, and the reader
was kept blinded to the radiology re-
ports, clinical and laboratory details,
and treatment information. Image anal-
ysis was performed on a picture archiv-
ing and communication system (Agfa,
Richmond, Va), and the readings were
recorded in a systematic fashion on a
predesigned template, which was later
transferred to a standardized database
(N.I.S.).
Pre-CST CT studies.—Pretreatment
sequential multidetector CT studies
were evaluated for all 15 patients to
study the disease evolution (D.V.S.).
Presence of pancreatic swelling, whether
focal (when only a part of the pancreas
was involved) or diffuse (involving the
entire pancreas), was recorded. The
pancreas was considered to be swollen
subjectively when there was partial or
complete obscuration of lobular archi-
tecture. A complete loss of pancreatic
lobulation and absence of normal pan-
creatic clefts was described as a “fea-
tureless” pancreas. Focal masslike
swelling was defined as focal enlarge-
ment without pancreatic or peripancre-
atic inflammatory changes. Enhance-
ment of the pancreatic parenchyma was
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subjectively described as homogeneous
or heterogeneous. Involution of the pan-
creatic tail, or “tail cutoff,” was consid-
ered to be present when there was
abrupt blunting and retraction of the
tail. The presence of parenchymal atro-
phy, calcification, or stones was as-
sessed. The peripancreatic region was
evaluated for stranding (represented by
streaking of peripancreatic fat), a hy-
poattenuating rim surrounding the pan-
creas (referred to as a “halo”), and any
fluid collections. The PD and CBD were
assessed for focal or diffuse changes
such as narrowing or stricture, dilata-
tion, and abnormal enhancement. In ad-
dition, the presence of peripancreatic
lymphadenopathy and the status of
peripancreatic vessels were evaluated.
Quantitative analysis was per-
formed on the CT study available just
before the start of CST and included
anteroposterior measurements of the
pancreatic head (at the level of the
portosplenic confluence), neck (ante-
rior to the portal vein), body (to the
left of the superior mesenteric artery
at the level of the left renal vein), and
tail (about 1 cm proximal to the distal
end of the pancreas). The widest
thickness of any halo and the short-
axis diameter of the lymph nodes were
also recorded. The widest diameter of
the dilated CBD was measured on the
baseline study (N.I.S.). These measure-
ments were then transferred to the
standardized database (N.I.S.).
Post-CST CT studies.—To evaluate
the response to CST, CT findings before
and after CST were compared in 13 pa-
tients (D.V.S.). Favorable response was
suggested by partial or complete resolu-
tion of focal or diffuse swelling, recov-
ery of pancreatic lobularity and tail, reso-
lution of peripancreatic stranding and
halo, and recovery of PD and CBD mor-
phology. Partial response also included
resolution of some features, with persis-
tence or stability of others. Increase in
the above-mentioned findings, develop-
ment of focal PD or CBD stricture with
upstream dilatation, or evidence of any
new findings that were not present on
previous studies indicated disease pro-
gression. Quantitative analysis of pan-
creatic size was performed on the last
available CT study for each patient after
they had received CST (N.I.S.). The
change in pancreatic size before and af-
ter CST was analyzed for a significant
difference by using the Wilcoxon signed
rank test. P  .05 was considered to
indicate a statistically significant differ-
ence.
Results
Clinical Features and Laboratory Data
Pretreatment.—The symptoms at presen-
tation included abdominal pain (n  11),
jaundice (n 9), fatigability (n 9),weight
loss (n  6), nausea and/or vomiting (n 
5), pruritus (n 2), back pain (n 1), new
onset of diabetes (n2), andno symptoms
(n 1). None of the patients had a history
of pancreatitis or alcohol abuse. Four pa-
tients had associated autoimmune diseases
(primary sclerosing cholangitis, Sjo¨gren
syndrome, Behc¸et disease, and rheumatoid
arthritis). Serum IgG levels (available in 13
patients) were elevated in three patients,
while IgG4 levels (available in nine patients)
were elevated in eight patients (Tables 1,
E1 [http://radiology.rsnajnls.org/cgi
/content/full/2493080279/DC1].
Posttreatment.—After CST, com-
plete resolution of symptoms was seen
in eight of 13 patients, while in five pa-
tients, partial resolution was recorded
Figure 1
Figure 1: Serial contrast-enhanced CT images through pancreas in 84-year-old woman who presented
with abdominal pain, jaundice, and weight loss and had complete response to CST. (a)Axial image from initial
examination reveals normal pancreasmorphology but minimal prominence of PD (arrow). (b)Axial and
(c) coronal images from subsequent study performed at 2-month interval shows diffuse pancreatic swelling
with loss of lobularity and a subtle halo around the pancreas (arrows in b). The PD is now attenuated (not visu-
alized), and the pancreatic tail appears foreshortened (arrow in c). (d)Coronal image obtained after 2months
of CST reveals near complete resolution of pancreatic swelling and peripancreatic changes. Note that paren-
chymal lobularity has reappeared and that the PD (short arrow) is now visualized. Additionally, recovery of the
pancreatic tail (long arrow) is observed.
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(Tables 2, E1 [http://radiology.rsnajnls
.org/cgi/content/full/2493080279/DC1].
The latter five patients had persistent
abdominal pain or varying degrees of
other reported symptoms (jaundice in
one patient, pruritus in another). Com-
plete resolution of symptoms occurred
within a 2–12-month interval (mean,
5.4 months). Gradual improvement in
IgG and IgG4 levels was also noted in
the patients when these levels were
available, except in two patients with
partial resolution of clinical symptoms
in whom mild IgG4 elevation persisted
(Tables 2, E1 [http://radiology.rsnajnls.org
/cgi/content/full/2493080279/DC1].
Multidetector CT Image Analysis
Pre-CST CT studies.—The changes ob-
served before institution of CST on CT
studies in 15 patients in the evaluation
of disease evolution are listed in Tables
1 and E1 (http://radiology.rsnajnls.org
/cgi/content/full/2493080279/DC1). The
number of pretreatment CT examina-
tions and the time interval at which
these examinations were performed
varied for each patient. All patients un-
derwent a minimum of two CT examina-
tions, whereas four patients underwent
four pretreatment examinations; the
imaging interval ranged from 1 to 31
months (mean, 6.5 months).
At the initial CT examination, vary-
ing degrees of diffuse pancreatic swell-
ing with loss of lobularity were observed
in 14 of 15 patients (Figs 1, 2); one
patient had fullness of the pancreatic
parenchyma with preserved lobularity.
These features gradually evolved to in-
crease in swelling and/or loss of lobular-
ity manifesting as a featureless “sau-
sage-shaped” pancreas. In one patient
(patient 8), the disease started as a fo-
cal swelling in the tail and then, over a
period of 19 months, progressed to dif-
fuse swelling and a featureless pancreas
(Fig 3). In 10 patients, gradually in-
creasing heterogeneous enhancement
was observed in the swollen pancreas.
Pancreatic tail retraction was noted at
the baseline CT examination in eight pa-
tients and was observed to develop on
follow-up CT studies in the other six
patients. Retraction increased at fol-
low-up examinations in five patients and
remained stable in seven. Progression
of disease thus incited or augmented
retraction of the tail (Figs 1, 2). Peripan-
creatic findings (stranding [n  10]
and/or halo [n  9]) noted at the base-
line examination in nine patients paral-
leled the pancreatic changes, evolving
and/or becoming more severe at fol-
low-up examinations (Figs 1, 2).
Quantitatively, the maximum an-
teroposterior dimensions of the pan-
creas at the CT examination performed
prior to the initiation of CST were as
follows: head, 24–48 mm (mean, 32.2
mm  6.9 [standard deviation]); neck,
6–24 mm (14.3 mm  5.6); body,
15–31 mm (22 mm  5.1); and tail,
11–30 mm (21.8 mm  6.8). The thick-
ness of the halo ranged from 1 to 10 mm
(4.7 mm  2.8). The dimensions of the
pancreas and the thickness of halo in-
creased as the disease evolved. There
was associated attenuation of the PD in
10 of 15 patients that was caused by
swelling in the surrounding pancreatic
parenchyma (Figs 1, 2). In four pa-
tients, the PD initially appeared promi-
nent, and, as the parenchymal swelling
progressed, diffuse attenuation of the
PD occurred (Fig 1), whereas in one
Figure 2
Figure 2: (a–d) Axial contrast-enhanced CT images through pancreas in 58-year-old man who presented
with jaundice and abdominal pain and who demonstrated a partial response to CST. Images a and bwere
obtained before and c and dwere obtained 8months after CST. (a, b) Focal prominent swelling is seen in the
head of the pancreas (arrowheads); diffuse swelling, loss of lobularity, halo (short arrows) in the region of the
body and tail, and retraction of the tail (long arrow) are also seen. (c, d) Follow-up images reveal reduction in
the size of the focal swelling in the pancreatic head (arrowheads) and partial resolution of pancreatic swelling
and halo (short arrows). The retraction of the tail (long arrow) persisted.
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patient, the PD was irregularly nar-
rowed. The distal CBD showed smooth
tapering due to swelling in the pancre-
atic head in 12 patients, in three of
whom thick enhancing walls of the CBD
were noted. There were associated
variable degrees of dilatation of the
proximal CBD (widest diameter range,
8–16 mm; mean, 11.4 mm [as mea-
sured at the baseline examination]) and
intrahepatic biliary radicals in all of
these patients. Eight of the 12 patients
underwent stent placement for pallia-
tive relief of biliary obstruction, and in
the remaining patients, these obstruc-
tive changes either gradually pro-
gressed (n 2) or remained stable (n
2). None of the patients had parenchy-
mal calcification, stones, or atrophy at
the pretreatment CT examinations. One
patient (patient 8) developed a cystic
lesion with attenuation of fluid in the
body of the pancreas during the course
of the disease; this lesion, however, re-
solved at follow-up imaging before CST.
Peripancreatic lymph node enlargement
was observed in eight of 15 patients
during the course of the disease. The
size of the lymph nodes ranged from 6
to 13 mm.
Post-CST CT studies.—The changes
observed at CT examinations in 13 pa-
tients treated with CST are listed in Ta-
bles 2 and E1 (http://radiology.rsnajnls
.org/cgi/content/full/2493080279/DC1).
The number of posttreatment CT exam-
inations and the time interval at which
these examinations were performed for
each patient varied. All patients under-
went a minimum of one posttreatment
CT examination, while in two patients,
three posttreatment CT studies were
Figure 3
Figure 3: Sequential axial CT images through pancreas in 72-year-old man who eventually developed atrophy of the pancreas after CST. (a) Image from initial exami-
nation showsmild fullness in the tail (arrow) that worsened gradually over an 8-month period on (b, c) images from two subsequent CT examinations (6 and 8months
from baseline, respectively). (d) The disease in the pancreas then evolved over next 18months into diffuse swelling (arrowheads), retraction of the tail (arrow), and loss of
lobularity. The patient had jaundice and pruritus at this stage. (e) The head of the pancreas at this stage (18months from baseline) also appears enlarged (arrow), but the
focal changes in the tail noted on prior studies have resolved. (f)A course of CSTwas given that resulted in complete resolution of pancreatic swelling 22months from
baseline, with changes of atrophy in the pancreas (arrow).
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available. The total posttreatment time
duration ranged from 2 to 23 months
(mean, 8.3 months).
Complete resolution of pancreatic
changes (swelling, loss of lobularity,
heterogeneity, tail retraction), peripan-
creatic changes, and ductal changes was
recorded in four (patients 1, 8, 9, and
10) of 13 patients (Fig 1) over a period
of 5 months to 1 year (mean, 7.7
months). Among these patients, im-
provement in parenchymal swelling and
peripancreatic stranding and/or halo
was the most notable finding. These
changes gradually improved to com-
plete resolution, and, finally, the pan-
creas appeared slightly atrophied than
usually expected in two patients (pa-
tients 8 and 10) (Fig 3). The atrophy
developing in some patients at follow-up
evaluation has been attributed to acinar
loss (20,21). The ductal changes also
gradually resolved in parallel with the
parenchymal swelling (Fig 1). Regional
lymphadenopathy resolved in six of
eight patients (3,22,23). These de-
scribed imaging manifestations that fa-
vorably responded to CST have been
attributed to inflammatory changes
(13,20,24). Complete resolution of clin-
ical and serologic parameters (when
available) was noted in these patients (Ta-
bles 2, E1 [http://radiology.rsnajnls
.org/cgi/content/full/2493080279/DC1].
Partial response was observed in
nine of 13 patients at follow-up exami-
nations over a period of 2–23 months
(mean, 8.2 months). The parenchymal
changes (swelling, loss of lobularity,
heterogeneity) partially improved in five
of the nine patients, and peripancreatic
changes improved in two of the nine
patients (Fig 2). In seven of nine pa-
tients with partial response, retraction
of the tail persisted (Fig 2). In another
seven of nine patients, diffuse swelling
in the body and tail showed obvious im-
provements; however, a more focal
masslike swelling in the head either re-
mained unchanged (in five of seven pa-
tients) or showed minimal improvement
(in two of seven patients) (Figs 2, 3).
Three of these patients with persistent
swelling in the head (patients 11, 12,
and 13) later underwent surgery to re-
lieve symptoms. The manifestations in
the CBD and PD also resolved partially
in five of nine and seven of nine pa-
tients, respectively (Fig 3). In two of the
patients with PD changes (patients 11
and 13), the PD changes progressed to a
focal stricture in the head (disease pro-
gression); in these patients, there were
other associated chronic changes (per-
sisting focal masslike swelling and/or at-
rophy) (3,13). Focal masslike swelling,
persistent retraction of the tail, and
ductal strictures were the features ob-
served late in the evolution of disease
and have been attributed to chronicity
and the inception of fibrotic changes
(3,13). In one patient with diffuse
changes in the pancreas and an associ-
ated focal masslike lesion in the head
(patient 6), substantial improvement
was noted at imaging and in clinical
symptoms 6 weeks after CST; there-
fore, CST was terminated. However, at
follow-up CT examination 6 months af-
ter the institution of CST, focal swelling
developed in the tail, and CST was
therefore reinstituted. Subsequent CT
studies over 2 months demonstrated
marked improvement in the pancreatic
changes. Eight patients with CBD dila-
tation underwent stent placement; the
stents were removed later as the pa-
tients’ conditions improved clinically
and radiologically (at multidetector CT
and/or ERCP). Among nine patients
with partial response at imaging, partial
resolution of symptoms was noted in
five patients (two patients with focal
swelling in the pancreatic head and PD
stricture, one patient with focal swelling
in the pancreatic head, and two other
patients), while in the remaining pa-
tients, the symptoms resolved com-
pletely. Results of serologic examina-
tion, when available, revealed improve-
ment after CST (Tables 2, E1 [http:
//radiology.rsnajnls.org/cgi/content/full
/2493080279/DC1].
The quantitative dimensions of the
pancreas on the last available CT stud-
ies for the patients treated with CST
were as follows: pancreatic head, 17–28
mm (23.1 mm  4.2); neck, 6–16
mm (10.4 mm  3.2); body, 10–28 mm
(17.5 mm  4.6); and tail, 11–25 mm
(17.1 mm 3.9). Differences in the size
of the pancreas measured before and
after CST were statistically significant
(head, P  .003; neck, P  .007; body,
P  .0002; and tail, P  .003).
Discussion
AIP, first described by Sarles et al in
1961 (25) as “primary inflammatory
sclerosis” of the pancreas, was later un-
derstood to be a variant of chronic pan-
creatitis invoked by an autoimmune
process; hence, the currently accepted
terminology of “autoimmune pancreati-
tis” has come into existence (16,22).
The widely accepted criteria for the di-
agnosis of AIP are those developed by
the Japan Pancreas Society in 2002 and
revised in 2006, which include imaging,
serologic, and pathologic criteria (25,
26). The HISORt criteria of the Mayo
Clinic in 2006 (13) include extrapancre-
atic manifestations and response to CST
in addition to the above-mentioned cri-
teria. Although the diagnostic criteria for
AIP have been well described, the evolu-
tion of the disease is not well understood,
despite its potential relevance in selecting
an appropriate treatment strategy. In our
study, CST was initiated in the patients
because of strong suspicion of AIP on the
basis of clinical manifestation, laboratory
values (elevated IgG4 levels), and imaging
features such as sequential multidetector
CT findings over time and findings at
ERCP and/or endoscopic US with fine-
needle aspiration cytology that were con-
sistent with diagnosis. Invasive proce-
dures such as biopsy were not routinely
performed for histopathologic confirma-
tion in the cohort of patients included in
our study (5,13,27–29). The favorable re-
sponse to CST objectively monitored with
multidetector CT further supports the
fact that imaging features, in conjunction
with clinical and relevant laboratory data
(when reviewed cautiously), in patients
with a high level of suspicion of AIP can be
regarded as sufficient evidence to initiate
a trial of CST.
The spectrum of imaging features of
AIP at CT have been described in the
literature (8–10). Moreover, differences in
the degree of response to CST, from
normalization of pancreatic and ductal
changes (7,9,13,16,30) to persistence
of focal masslike lesions and develop-
GASTROINTESTINAL IMAGING:CT of Autoimmune Pancreatitis Sahani et al
Radiology: Volume 250: Number 1—January 2009 127
ment of ductal strictures, have been re-
ported (8,30). These observations sug-
gest that this array of imaging manifes-
tations could represent different phases
in disease evolution, analogous to the
staging proposed by Zamboni et al (3)
on the basis of differences in the extent
of inflammatory changes and fibrosis.
Analyzing the course of events at CT,
we observed that the disease mani-
fested as diffuse or focal swelling in the
pancreas. Without treatment, these
changes progressed into worsening pan-
creatic swelling and complete loss of pa-
renchymal lobularity, resulting in a fea-
tureless, sausage-shaped pancreas
(8,11). Concurrent progression of pan-
creatic tail retraction, peripancreatic
findings, and ductal changes was also
noted. The disease started as a focal
swelling in one patient that later ad-
vanced to involve the gland diffusely.
This finding suggests that AIP can start
as a focal, low-grade inflammation in
the pancreas that results in nonspecific
symptoms for which the patients may
not seek medical attention. As the dis-
ease progresses into a diffuse form, pa-
tients can experience symptoms that re-
quire a visit to the physician. Similar
observation of the evolution of focal
into diffuse changes was also made by
Hirano et al (30). As in earlier studies,
in our study, diffuse pancreatic swelling,
peripancreatic changes, and ductal oblit-
eration or thickening (when present) re-
sponded favorably to CST treatment in
all patients in a short time frame (1
month in a few patients), thus support-
ing the hypothesis of the presence of an
underlying active inflammatory process
(13,16,20,24). Incomplete resolution of
the discussed changes observed in a few
patients in our study could be attributed
to a slower responder or to inadequate
availability of follow-up studies. Focal
masslike swelling (when present without
peripancreatic inflammatory changes),
persistent focal ductal narrowing (stric-
ture formation), and tail retraction in
some cases reflected suboptimal re-
sponse to CST and exemplify late events
in the disease evolution that are likely
due to the inception of fibrosis or diffuse
sclerosis (3,13,31). Persisting focal
masslike swelling can masquerade as
pancreatic carcinoma clinically and at
imaging and often requires surgical re-
section to alleviate the patient’s symp-
toms (3,17,20,24,29). Also, to avoid
any delay in treating a veiled malig-
nancy, surgical exploration has been
recommended for corticosteroid-
treated focal masslike swellings that do
not show improvement at follow-up im-
aging, as observed in some of our pa-
tients (13). The observation of resolu-
tion of ductal narrowing in some cases
and lack of resolution with development
of stricture despite treatment in others
suggests that CST, if instituted early in
the course of the disease, results in a
favorable outcome as it can avert evolu-
tion to the late stage of disease. Hirano
et al (30) also found CST to be particu-
larly useful in preventing ductal lesions.
Development of a pancreatic cyst in as-
sociation with AIP that disappears nat-
urally, which was seen in one of our
patients, has also been reported by Na-
kazawa et al (10) and has been attrib-
uted to ductal stenosis with formation of
a retention cyst.
The duration of CST is currently not
standardized, as in a few patients, more
than one course of therapy may be re-
quired because of recurrence or devel-
opment of new imaging findings at ces-
sation of CST, as observed in our study.
Other investigators (7,14,30) have also
made similar observations, and patients
with partial response to CST may re-
quire reinstitution of CST at similar or
higher doses. CST may also be needed
after surgery because of the develop-
ment of new imaging findings; a new
intrahepatic biliary stenosis was re-
ported in one patient after pancre-
atoduodenectomy by Nakazawa et al
(10). For the same reason, regular
clinical, serologic, and imaging fol-
low-up is prudent for monitoring dis-
ease status in patients with incomplete
response (14,30).
Our study had a number of limita-
tions. We did not have control over sev-
eral factors in this retrospective study.
The scanning parameters and protocol,
the type and volume of intravenous con-
trast material, and the types of pred-
nisone used were not consistent. Labo-
ratory parameters, especially serologic
results, were not available in all patients
or at all time points when CT examina-
tions were performed to establish cor-
relation. Specific inclusion criteria re-
sulted in a small cohort, which limited
correlating demographic (age and sex)
patterns with CT results. Detection of
disease at a different phase at the base-
line CT examination in each patient and
the variable time interval at which the
pretreatment and posttreatment exami-
nations were performed for all patients
prevented relating development or evo-
lution of a specific imaging feature with
a specific time interval. However, this
situation is very commonly encountered
in this disease, as many patients present
in the postacute phase, a variable time
interval after the onset of the disease
process (10,13). Moreover, the partial
response observed in some patients
could be partly related to the unavail-
ability of follow-up studies until com-
plete resolution. Finally, a single reader
aware of the purpose of the study evalu-
ated all the imaging studies.
In conclusion, knowledge of the
morphologic evolution of AIP and recog-
nition of the imaging features at CT that
can predict outcome after CST might
be crucial in deciding the appropriate
treatment for patients with this disease.
In our experience, pancreatic swelling
with peripancreatic changes, including
the halo, represents an early or inflam-
matory dominant phase of the disease
that responds favorably to CST. Focal
masslike swelling, especially in the pan-
creatic head, without diffuse pancreatic
and peripancreatic changes and devel-
opment of focal PD strictures are mani-
festations of a late disease stage with
predominance of fibrosis and less de-
gree of inflammation and are predictive
of a suboptimal outcome after CST, fre-
quently requiring surgical intervention.
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